OR WAIT 15 SECS
Emergent is entering into a five-year agreement with Janssen Pharmaceuticals for the large-scale drug substance manufacturing of Johnson & Johnson’s investigational COVID-19 vaccine, Ad26.COV2-S.
Emergent BioSolutions announced on July 6, 2020 that it is entering into a five-year, $480 million manufacturing services agreement with Janssen Pharmaceuticals, a Johnson & Johnson company, for the large-scale drug substance manufacturing of Johnson & Johnson’s investigational COVID-19 vaccine, Ad26.COV2-S.
Through the agreement, Emergent will offer large-scale manufacturing at its Bayview facility in Baltimore, MD, an Emergent press release said. Starting in 2023, Emergent will provide a flexible capacity deployment model to support additional drug substance batches annually.
“We are proud to deploy our manufacturing strength to address the COVID-19 pandemic,” said Robert G. Kramer Sr., president and CEO of Emergent, in the press release. “Advancing this collaboration is one of the ways we live our mission – to protect and enhance life.”
“Over the next five years, we are committing our [contract development and manufacturing organization] (CDMO) services to advance this important vaccine candidate,” said Syed T. Husain, senior vice president and CDMO business unit head at Emergent, in the press release. “We have the expertise and capabilities to meet the long-term needs of our customers and provide ongoing commercial manufacturing to benefit patients.”